The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on 2023-10-23. This approval pertains to an efficacy supplement, indicating an expansion of the drug's approved uses based on new efficacy data.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab) signifies an expansion of its approved therapeutic applications. While the specific new indication or patient population is not detailed in this event record, the approval for "Efficacy" confirms that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness for an additional use. This allows clinicians to prescribe Keytruda for this newly approved purpose, potentially benefiting more patients. The sponsor for this application was Merck Sharp Dohme.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on 2023-10-23. The details are available on the accessdata.fda.gov website, pertaining to supplemental application BLA125514 S-142 for Keytruda (pembrolizumab).